Discovery of 4-(5-methyloxazolo [4, 5-b] pyridin-2-yl)-1, 4-diazabicyclo [3.2. 2] nonane (CP-810,123), a novel α7 nicotinic acetylcholine receptor agonist for the …

CJ O'Donnell, BN Rogers, BS Bronk…

Index: O'Donnell, Christopher J.; Rogers, Bruce N.; Bronk, Brian S.; Bryce, Dianne K.; Coe, Jotham W.; Cook, Karen K.; Duplantier, Allen J.; Evrard, Edelweiss; Hajos, Mihaly; Hoffmann, William E.; Hurst, Raymond S.; Maklad, Noha; Mather, Robert J.; McLean, Stafford; Nedza, Frank M.; O'Neill, Brian T.; Peng, Langu; Qian, Weimin; Rottas, Melinda M.; Sands, Steven B.; Schmidt, Anne W.; Shrikhande, Alka V.; Spracklin, Douglas K.; Wong, Diane F.; Zhang, Andy; Zhang, Lei Journal of Medicinal Chemistry, 2010 , vol. 53, # 3 p. 1222 - 1237

Full Text: HTML

Citation Number: 44

Abstract

A novel α7 nAChR agonist, 4-(5-methyloxazolo [4, 5-b] pyridin-2-yl)-1, 4-diazabicyclo [3.2. 2] nonane (24, CP-810,123), has been identified as a potential treatment for cognitive deficits associated with psychiatric or neurological conditions including schizophrenia and Alzheimer's disease. Compound 24 is a potent and selective compound with excellent pharmaceutical properties. In rodent, the compound displays high oral bioavailability and ...